Quintara Biosciences, Inc. v. Ruifeng Biztech Inc.

District Court, N.D. California·Decided December 10, 2020·No. 3:20-cv-04808·Unknown

Opinion

1 2 3 4 5 6 UNITED STATES DISTRICT COURT 7 NORTHERN DISTRICT OF CALIFORNIA 8

10 QUINTARA BIOSCIENCES, INC., 11 Plaintiff, No. C 20-04808 WHA

12 v.

13 RUIFENG BIZTECH INC., et al., ORDER RE MOTION TO AMEND AND VACATING HEARING 14 Defendants.

15 16 Quintara Biosciences, Inc., timely moves to amend its complaint to: (i) plead appropriate 17 Section 17200 relief; (ii) clarify dates regarding notice provisions under the Defend Trade 18 Secrets Act; (iii) add a claim for intentional interference with contractual relations; and (iv) 19 salvage its fraud claim. Except for the final request, the motion is GRANTED. 20 The October 16 order dismissed the Section 17200 claim for seeking damages and not 21 restitution. That has been corrected and defendants point to no reason that the underlying 22 conversion and duty of loyalty claims would not support restitution and injunction. The claim 23 may proceed. 24 The prior order also dismissed Quintara’s claim for attorney’s fees and exemplary 25 damages under the DTSA against its former employees, Alex Wong, Alan Li, and Rui Shao. 26 An employer must have provided written notice to its employees of the DTSA’s whistleblower 27 protections before it may recover exemplary damages and attorney’s fees for their trade secret 1 and agreements that are entered into or updated after the date of enactment of this subsection 2 [May 11, 2016].” The prior complaint did not plead when the employees entered their 3 operative NDAs. The new compliant does: Wong in December 2009; Shao in February 2011; 4 and Li in April 2013. Each preceding the DTSA, the notice provision, by its plain language, 5 does not apply. Defendants say this result is absurd, but provide no caselaw or legislative 6 history to warrant deviation from the plain text. At this stage, Quintara may seek exemplary 7 damages and attorney’s fees against Wong, Li, and Shao. 8 Quintara also seeks to add a claim for intentional interference with contractual relations. 9 On the merits, defendants contend only that the complaint fails to specify the contracts 10 interfered with. But, as defendants also note, a plaintiff may “recover damages for interference 11 with prospective economic advantage” where “the defendant’s conduct was ‘wrongful by some 12 legal measure other than the fact of interference itself.’” Here, the complaint alleges 13 defendant’s interference with Quintara’s sales upon defendants’ conversion, disloyalty, and 14 misappropriation. Ixchel Pharma, LLC v. Biogen, Inc., 9 Cal. 5th 1130, 1142, 470 P.3d 571 15 (2020). Defendants also claim undue delay, but cite no prejudice. This is Quintara’s first 16 amendment, as of right. The claim may proceed. 17 Quintara’s fraud claim still fails. The complaint again alleges that defendant Gangyou 18 Wang induced Quintara to enter a series of arrangements which he represented as necessary for 19 a visa application, but which, in fact, enabled his later takeover of the business. In fraud “[a] 20 plaintiff’s reliance on a defendant’s misrepresentation must be justifiable in light of plaintiff’s 21 own intelligence and information.” The October 16 order found Quintara’s reliance on Wang’s 22 representations unjustified. In aiding Wang in a plot which it suspected to be an illicit 23 deception of the United States government, Quintara willfully ignored the warnings that Wang 24 had also misled Quintara (Dkt. No. 28) (quotations omitted) 25 The amended complaint confirms this conclusion. It admits that Quintara was larger and 26 more sophisticated than the prior order understood, that Quintara knew that Wang’s visa 27 application fell apart under minimal investigation by immigration officials in 2017, and 1 “sophisticated” technology startup, with thirty-six employees and a three-million dollar 2 payroll, took an unwritten one-million dollar loan with significant strings attached from a new 3 business partner in 2013, entered an illusory joint-ownership collaboration agreement shortly 4 thereafter, and in 2017 agreed to a lease name swap. Each of these, Quintara suspected to be 5 illicit, knew to be aimed at misleading United States immigration officials, and knew those 6 officials reached the same conclusion in 2017. Yet, Quintara never consulted counsel until 7 after Wang sprung his trap to take over the business in 2020. A multi-million dollar 8 technology company that proceeds through seven years of expansion, business deals, corporate 9 and employee tax filings, along with unwritten million dollar loans, illusory collaboration 10 agreements, and suspect real estate deals without consulting counsel has deliberately buried its 11 head in the sand (Dkt. No. 34-1 at J 17, 21, 31, 32, 42, 76). 12 The amended complaint argues that Quintara’s founders’ cultural background justified 5 13 their reliance on Wang’s statements to them. This twice misses the mark. The knowledge of 14 Wang's misrepresentations to the government gave Quintara reason to investigate Wang’s 15 representations to itself. Moreover, Quintara’s individual founders are not our plaintiffs. Our 16 plaintiff here, and the party whose reliance must be justified, is Quintara, the multimillion- 3 17 dollar technology company operating under California law. 18 The motion is GRANTED IN PART. Quintara’s fraud claim still fails. But its claims for 19 exemplary damages and attorney’s fees for trade secret misappropriation against Wong, Li, and 20 Shao, for restitution and injunction under Section 17200, and for intentional interference with 21 contractual relations may proceed. The amended answer iscdue ‘DECEMBER 22. The December 22 17 hearing is VACATED. 23 IT IS SO ORDERED. 24 25 Dated: December 8, 2020. 26 27 A = J ™ LIAM ALSUP 28 UNITED STATES DISTRICT JUDGE

Free access — add to your briefcase to read the full text and ask questions with AI

Quintara Biosciences, Inc. v. Ruifeng Biztech Inc., (N.D. Cal. 2020).

Quintara Biosciences, Inc. v. Ruifeng Biztech Inc. (Quintara Biosciences, Inc. v. Ruifeng Biztech Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Ixchel Pharma, LLC v. Biogen, Inc.
470 P.3d 571 (California Supreme Court, 2020)